Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,773
  • Shares Outstanding, K 74,721
  • Annual Sales, $ 1,330 K
  • Annual Income, $ -32,950 K
  • 60-Month Beta 2.28
  • Price/Sales 15.71
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLSD with:

Options Overview Details

View History
  • Implied Volatility 139.47% ( +6.41%)
  • Historical Volatility 101.27%
  • IV Percentile 8%
  • IV Rank 8.41%
  • IV High 1,014.46% on 08/30/23
  • IV Low 59.18% on 04/17/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 35
  • Volume Avg (30-Day) 164
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,319
  • Open Int (30-Day) 1,727

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.16
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +30.00%
on 02/20/24
2.1200 -26.42%
on 03/12/24
+0.3100 (+24.80%)
since 02/16/24
3-Month
0.9900 +57.58%
on 12/20/23
2.1200 -26.42%
on 03/12/24
+0.5300 (+51.46%)
since 12/18/23
52-Week
0.6501 +139.96%
on 10/26/23
2.1200 -26.42%
on 03/12/24
+0.5200 (+50.00%)
since 03/17/23

Most Recent Stories

More News
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.14% and 98.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

CLSD : 1.5600 (-8.77%)
AFMD : 4.54 (-0.66%)
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of -27.40% and 119.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

TCRX : 6.83 (-4.07%)
CLSD : 1.5600 (-8.77%)
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 74.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RXDX : 199.92 (+0.09%)
CLSD : 1.5600 (-8.77%)
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of 26.67% and 79.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ALEC : 6.00 (-1.96%)
CLSD : 1.5600 (-8.77%)
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

CLSD : 1.5600 (-8.77%)
AEZS : 2.10 (-3.23%)
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

RGNX : 22.33 (+0.63%)
CLSD : 1.5600 (-8.77%)
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BPMC : 86.82 (-4.07%)
CLSD : 1.5600 (-8.77%)
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

CLSD : 1.5600 (-8.77%)
EVGN : 0.8090 (-1.34%)
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 23.17 (-1.19%)
CLSD : 1.5600 (-8.77%)
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

WVE : 5.67 (-12.77%)
CLSD : 1.5600 (-8.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

3rd Resistance Point 2.0199
2nd Resistance Point 1.8999
1st Resistance Point 1.7300
Last Price 1.5600
1st Support Level 1.4401
2nd Support Level 1.3201
3rd Support Level 1.1502

See More

52-Week High 2.1200
Last Price 1.5600
Fibonacci 61.8% 1.5585
Fibonacci 50% 1.3850
Fibonacci 38.2% 1.2116
52-Week Low 0.6501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar